FY2026 EPS Estimates for OPKO Health Lifted by HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – Investment analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of OPKO Health in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings of ($0.18) per share for the year, up from their prior forecast of ($0.23). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for OPKO Health’s Q4 2026 earnings at ($0.11) EPS, Q1 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.27) EPS.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $130.83 million during the quarter, compared to the consensus estimate of $136.62 million. OPKO Health had a negative return on equity of 10.66% and a negative net margin of 29.51%. OPKO Health’s revenue was down 56.9% on a year-over-year basis. During the same period last year, the business posted $0.03 earnings per share.

Several other equities research analysts have also issued reports on the company. Piper Sandler reaffirmed an “overweight” rating and set a $4.00 target price (up from $3.00) on shares of OPKO Health in a research report on Friday, October 16th. Barrington Research raised shares of OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 price target on the stock in a report on Friday, October 16th. Zacks Research raised shares of OPKO Health from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, August 13th. Finally, UBS Group set a $4.00 price objective on shares of OPKO Health in a report on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, OPKO Health has a consensus rating of “Moderate Buy” and a consensus price target of $3.42.

OPKO Health Stock Down 1.2%

OPK stock opened at $1.71 on Monday. The stock’s fifty day simple moving average is $1.59 and its two-hundred day simple moving average is $1.36. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28. OPKO Health has a 1-year low of $0.98 and a 1-year high of $1.86. The stock has a market cap of $1.28 billion, a P/E ratio of -9.00 and a beta of 1.52.

Institutional Trading of OPKO Health

Hedge funds have recently made changes to their positions in the company. Fifth Third Bancorp lifted its position in shares of OPKO Health by 8.8% during the 3rd quarter. Fifth Third Bancorp now owns 185,000 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 15,000 shares during the last quarter. Two Sigma Securities LLC purchased a new stake in OPKO Health in the 2nd quarter worth about $27,000. Partners Wealth Management LLC bought a new stake in OPKO Health in the 3rd quarter valued at about $43,000. EP Wealth Advisors LLC bought a new stake in OPKO Health in the 2nd quarter valued at about $45,000. Finally, Diversify Advisory Services LLC purchased a new stake in OPKO Health during the second quarter valued at about $37,000. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.